Several other GLP-1 RAs have been approved to date for subcutaneous (s.c.) use to treat T2DM, including liraglutide in 2009 (Europe) and 2010 (USA), exenatide ER in 2012, lixisenatide in 2013 (Europe) and 2016 (USA), dulaglutide in 2014, albiglutide in 2014 (Europe and USA), and semaglutide in 2017 (USA) and 2019 (Europe)
The introduction of generics, such as Glenmarks liraglutide biosimilar launched at dramatically lower prices, reflects the push toward affordability and broader access in a cost-conscious market
Novo Nordisk (2016)
And, prescription-grade options, such as those offered by AgelessRx, are certified to be more pure and overall better quality
& Magyari, M
How to Increase Leptin Naturally and Lose Weight with TransformYou Enhancing leptin sensitivity naturally is a pivotal step towards sustainable weight loss and health improvement